Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC.FENC · Entity 5601 | Chief Commercial Officer | December 20, 2021 | December 20, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FENNEC PHARMACEUTICALS INC.
Report date December 20, 2021 · Filed December 20, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.08 · Expires 2031-12-20 | Direct | 75,000 |
Reported balance
After 2021-12-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-12-20 · Grant · Acquired 75,000 · Balance 75,000 F1: On December 20, 2021, Shubh Goel was granted an incentive stock option to purchase 75,000 shares of the Issuer's common shares pursuant to the Issuer's 2020 Equity Incentive Plan. F3: Item vests 100% upon FDA approval of PEDMARKTM. |
| Restricted Share Unit (right to receive value of a share)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2031-12-20 | Direct | 37,500 |
Reported balance
After 2021-12-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-12-20 · Grant · Acquired 37,500 · Balance 37,500 F2: On December 20, 2021, Shubh Goel was granted restricted share units to receive 37,500 shares of the Issuer's common shares pursuant to the Issuer's 2020 Equity Incentive Plan. F3: Item vests 100% upon FDA approval of PEDMARKTM. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 20, 2021, Shubh Goel was granted an incentive stock option to purchase 75,000 shares of the Issuer's common shares pursuant to the Issuer's 2020 Equity Incentive Plan.
F2: On December 20, 2021, Shubh Goel was granted restricted share units to receive 37,500 shares of the Issuer's common shares pursuant to the Issuer's 2020 Equity Incentive Plan.
F3: Item vests 100% upon FDA approval of PEDMARKTM.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 20, 2021 Filed Dec 20, 2021 22:49 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantRestricted Share Unit (right to receive value of a share) · Derivative | 37,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-151823 · tm2135965-3_4seq1.xml · derivative · entry 2 Goel Shubh · CIK 0001787942 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Shares · 37,500 shares Expires 2031-12-20 F2 · security: On December 20, 2021, Shubh Goel was granted restricted share units to receive 37,500 shares of the Issuer's common shares pursuant to the Issuer's 2020 Equity Incentive Plan. F3 · derivative.exercise_date: Item vests 100% upon FDA approval of PEDMARKTM. Read SEC document |
| December 20, 2021 Filed Dec 20, 2021 22:49 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $4.08 | $0.00 |
DisclosureSEC source: 0001104659-21-151823 · tm2135965-3_4seq1.xml · derivative · entry 1 Goel Shubh · CIK 0001787942 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 75,000 shares Expires 2031-12-20 F1 · security: On December 20, 2021, Shubh Goel was granted an incentive stock option to purchase 75,000 shares of the Issuer's common shares pursuant to the Issuer's 2020 Equity Incentive Plan. F3 · derivative.exercise_date: Item vests 100% upon FDA approval of PEDMARKTM. Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 15:59 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $7.53 | $0.00 |
DisclosureSEC source: 0001104659-21-076223 · tm2118436-3_4seq1.xml · derivative · entry 1 Goel Shubh · CIK 0001787942 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 100,000 shares Expires 2031-06-02 F1 · security: On June 3, 2021, Fennec Pharmaceuticals, Inc. announced that Shubh Goel was granted an incentive stock option to purchase 100,000 shares of the Issuer's common shares pursuant to the Issuer's 2020 Equity Incentive Plan. The date of the grant is June 2, 2021. F2 · derivative.exercise_date: 1/3 of the shares subject to this option shall vest immediately and may be exercised as of June 2, 2022 (the "Vesting Commencement Date"). 1/24 of the shares subject to this option shall vest immediately and may be exercised as of the last day of each month following the Vesting Commencement Date. As of May 31, 2024 and thereafter, 100% of the total number of shares subject to this option shall be vested. Read SEC document |
| May 15, 2020 Filed May 15, 2020 17:57 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $6.93 | $0.00 |
DisclosureSEC source: 0001104659-20-062411 · tm2019938d1_4.xml · derivative · entry 1 Goel Shubh · CIK 0001787942 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires 2030-05-15 F1 · security: On May 15, 2020, Fennec Pharmaceuticals, Inc. announced that Shubh Goel was granted an incentive stock option to purchase 25,000 shares of the Issuer's common shares pursuant to the Issuer's Amended and Restated Stock Option Plan. The date of the grant is May 15, 2020. F2 · derivative.exercise_date: 1/3 of the shares subject to this option shall vest immediately and may be exercised as of May 15, 2021 (the "Vesting Commencement Date"). 1/24 of the shares subject to this option shall vest immediately and may be exercised as of the last day of each month following the Vesting Commencement Date. As of May 15, 2023 and thereafter, 100% of the total number of shares subject to this option shall be vested. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 22:48 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $4.74 | $0.00 |
DisclosureSEC source: 0001144204-19-044292 · tv529267_4.xml · derivative · entry 1 Goel Shubh · CIK 0001787942 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Shares · 175,000 shares Expires 2029-09-09 F1 · security: On September 9, 2019, Shubh Goel was granted an incentive stock option to purchase 175,000 shares of the Issuer's common shares pursuant to the Issuer's Amended and Restated Stock Option Plan. F2 · derivative.exercise_date: 1/3 of the shares subject to this option shall vest and may be exercised as of September 9, 2020 (the "Vesting Commencement Date"). 1/24 of the shares subject to this option shall vest and may be exercised as of the last day of each month following the Vesting Commencement Date. As of September 9, 2022 and thereafter, 100% of the total number of shares subject to this option shall be vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.